The Government Accountability Office looked into how the FDA oversees medical devices and found that it does not review all class III devices (those with greatest risk, such as pacemakers) through its most stringent process.
It also found problems with the FDA’s postmarket surveillance of medical devices, reporting that the agency says it cannot review all of the reports it receives. The FDA also has not conducted all of the required inspections of manufacturing plants in the United States and overseas.
